Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
暂无分享,去创建一个
S. Connolly | E. Themeles | G. Hankey | P. Sheridan | M. Endres | S. Kasner | M. O’Donnell | N. Bornstein | A. Lindgren | G. Paré | P. Amarenco | Yilong Wang | Yongjun Wang | T. Tatlisumak | K. Muir | P. Lavados | S. Bangdiwala | O. Benavente | A. Arauz | A. Dávalos | B. Yoon | S. Uchiyama | C. Joyner | D. Toni | A. Członkowska | R. Brouns | Mukul Sharma | A. Shoamanesh | R. Mikulík | J. Eckstein | S. Berkowitz | D. Bereczki | R. Hart | W. Peacock | J. Weitz | R. Veltkamp | S. Ameriso | G. Peters | R. Gagliardi | W. Lang | G. Ntaios | S. Ozturk | F. Peacock | H. Mundl | L. Cunha | N. Shamalov | C. Pater | Balakumar Swaminathan | B. Kirsch | Matthys M De Vries Basson | Yongjun Wang | Matthys M. De Vries Basson
[1] W. Mueck,et al. The effect of food on the absorption and pharmacokinetics of rivaroxaban. , 2013, International journal of clinical pharmacology and therapeutics.
[2] Deborah M Caldwell,et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis , 2017, BMJ.
[3] David E. Thaler,et al. Long‐Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke , 2017, The New England journal of medicine.
[4] Frank Beckers,et al. Cryptogenic stroke and underlying atrial fibrillation. , 2014, The New England journal of medicine.
[5] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[6] J. Brachmann,et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design , 2017, International journal of stroke : official journal of the International Stroke Society.
[7] A. Mukherjee,et al. Cryptogenic Stroke. , 2016, The New England journal of medicine.
[8] G. Breithardt,et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF , 2012, The Lancet Neurology.
[9] Jean-Marc Schleich,et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke , 2017, The New England journal of medicine.
[10] J. Pogue,et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial , 2016, European stroke journal.
[11] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[12] Eric E. Smith,et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.
[13] P. Rothwell,et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study , 2015, The Lancet Neurology.
[14] S. Connolly,et al. Embolic strokes of undetermined source: the case for a new clinical construct , 2014, The Lancet Neurology.
[15] Helle K. Iversen,et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke , 2017, The New England journal of medicine.
[16] S. Connolly,et al. Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[17] R. Sacco,et al. Design of Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate vs. Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source (Re-Spect Esus) , 2015, International journal of stroke : official journal of the International Stroke Society.
[18] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[19] R. Hart,et al. Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas , 2005, Stroke.